Effects of fish oil supplements in NIDDM subjects. Controlled study - PubMed (original) (raw)

Clinical Trial

Effects of fish oil supplements in NIDDM subjects. Controlled study

T J Hendra et al. Diabetes Care. 1990 Aug.

Abstract

The aim of this study was to evaluate the effects of a fish oil preparation (MaxEPA) on hemostatic function and fasting lipid and glucose levels in non-insulin-dependent diabetic (NIDDM) subjects. Eighty NIDDM outpatients aged 55.9 yr (mean SD 11.5 yr) participated in a prospective double-blind placebo-controlled study of MaxEPA capsules (10 g/day) or olive oil (control) treatment over 6 wk. Patients received either MaxEPA or olive oil in addition to preexisting therapy. Metabolic and hemostatic variables were measured before treatment and after 3 and 6 wk. Platelet membrane eicosapentaenoic acid (EPA) content increased in the treatment group (P less than 0.001). MaxEPA supplementation was associated with a significant fall in total triglycerides (P less than 0.001) but did not affect total cholesterol (P = 0.7) compared with control treatment. Fasting plasma glucose increased after 3 wk (P = 0.01) but not after 6 wk (P = 0.17) treatment with MaxEPA. Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. An increase in clotting factor VII (P = 0.02), without changes in fibrinogen or factor X levels, occurred in the MaxEPA group. Similar reductions in blood pressure were observed in both groups. Dietary supplementation with MaxEPA capsules (10 g/day) in NIDDM subjects is associated with improvement in hypertriglyceridemia but with deleterious effects in factor VII and blood glucose levels. Most indices of platelet function are unaffected by this therapy.

PubMed Disclaimer

Cited by

Omega-3 Fatty Acids and Markers of Thrombosis in Patients with Atrial Fibrillation.
Reiner MF, Bertschi DA, Werlen L, Wiencierz A, Aeschbacher S, Lee P, Rodondi N, Moutzouri E, Bonati L, Reichlin T, Moschovitis G, Rutishauser J, Kühne M, Osswald S, Conen D, Beer JH. Reiner MF, et al. Nutrients. 2024 Jan 5;16(2):178. doi: 10.3390/nu16020178. Nutrients. 2024. PMID: 38257071 Free PMC article.
Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials.
Wang T, Zhang X, Zhou N, Shen Y, Li B, Chen BE, Li X. Wang T, et al. J Am Heart Assoc. 2023 Jun 6;12(11):e029512. doi: 10.1161/JAHA.123.029512. Epub 2023 Jun 2. J Am Heart Assoc. 2023. PMID: 37264945 Free PMC article.
The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature.
Derosa G, D'Angelo A, Maffioli P. Derosa G, et al. Phytother Res. 2022 Oct;36(10):3709-3765. doi: 10.1002/ptr.7564. Epub 2022 Aug 1. Phytother Res. 2022. PMID: 35912631 Free PMC article. Review.
Effects of fish oil supplementation on glucose control and lipid levels among patients with type 2 diabetes mellitus: a Meta-analysis of randomized controlled trials.
Gao C, Liu Y, Gan Y, Bao W, Peng X, Xing Q, Gao H, Lai J, Liu L, Wang Z, Yang Y. Gao C, et al. Lipids Health Dis. 2020 May 8;19(1):87. doi: 10.1186/s12944-020-01214-w. Lipids Health Dis. 2020. PMID: 32384902 Free PMC article.

Effects of fish oil supplements in NIDDM subjects. Controlled study - PubMed (original) (raw)